Indegene Ltd (INDGN) - Total Liabilities
Based on the latest financial reports, Indegene Ltd (INDGN) has total liabilities worth Rs14.82 Billion INR (≈ $160.23 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Indegene Ltd's assets to evaluate the company's liquid asset resilience ratio.
Indegene Ltd - Total Liabilities Trend (2020–2026)
This chart illustrates how Indegene Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INDGN total assets.
Indegene Ltd Competitors by Total Liabilities
The table below lists competitors of Indegene Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Permian Basin Royalty Trust
NYSE:PBT
|
USA | $2.25 Million |
|
SL Corp
KO:005850
|
Korea | ₩1.35 Trillion |
|
Kemper Corporation
NYSE:KMPR
|
USA | $9.75 Billion |
|
Top Glove Corporation Bhd
KLSE:7113
|
Malaysia | RM1.75 Billion |
|
Emlak Konut Gayrimenkul Yatirim Ortakligi AS
IS:EKGYO
|
Turkey | TL168.90 Billion |
|
Central Securities Corporation
NYSE MKT:CET
|
USA | $3.14 Million |
|
General American Investors Closed Fund
NYSE:GAM
|
USA | $17.21 Million |
|
DUERR AG UNSP.ADR 1/5
F:DUEB
|
Germany | €3.31 Billion |
Liability Composition Analysis (2020–2026)
This chart breaks down Indegene Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Indegene Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indegene Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indegene Ltd (2020–2026)
The table below shows the annual total liabilities of Indegene Ltd from 2020 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs14.82 Billion ≈ $160.23 Million |
+108.59% |
| 2025-03-31 | Rs7.10 Billion ≈ $76.82 Million |
-36.38% |
| 2024-03-31 | Rs11.16 Billion ≈ $120.75 Million |
-2.07% |
| 2023-03-31 | Rs11.40 Billion ≈ $123.30 Million |
+93.39% |
| 2022-03-31 | Rs5.90 Billion ≈ $63.76 Million |
+124.21% |
| 2021-03-31 | Rs2.63 Billion ≈ $28.44 Million |
-57.30% |
| 2020-03-31 | Rs6.16 Billion ≈ $66.60 Million |
-- |
About Indegene Ltd
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It al… Read more